Pharmaceutical Products
The Pharmaceutical Products segment’s products include a broad line of adult
and pediatric pharmaceuticals manufactured, marketed and sold worldwide, which
are sold primarily on the prescription, or recommendation, of physicians. In
2006, Abbott announced a collaboration with AstraZeneca to co-develop and market
a fixed-dose combination lipid management therapy of Crestor® (rosuvastatin/AstraZeneca)
with either Tricor® (Abbott’s fenofibrate) or Abbott’s next generation fenofibrate,
ABT 335.
The principal products included in the Pharmaceutical Products segment are:
· TriCor®, for the treatment of dyslipidemia;
· Niaspan®, for the treatment of high cholesterol;
· HUMIRA®, for the treatment of rheumatoid arthritis, psoriatic arthritis and
ankylosing spondylitis;
· the anti-infectives clarithromycin (sold under the trademarks Biaxin®, Klacid®
and Klaricid®), Omnicef®, an oral cephalosporin antibiotic, tosufloxacin, sold
in Japan under the trademark Tosuxacin®, and various forms of the antibiotic
erythromycin, sold primarily as PCE® or polymer-coated erythromycin, Erythrocin®,
and E.E.S.®;
· Synthroid®, for the treatment of hypothyroidism;
· Meridia® and Reductil® (also marketed as Reductyl™ and Reductal™) for the
treatment of obesity;
· the anti-virals Kaletra® and Norvir®, protease inhibitors for the treatment
of HIV infection;
· Depakote®, an agent for the treatment of epilepsy and bipolar disorder and
the prevention of migraines;
· the anesthesia products sevoflurane (sold in the United States under the
trademark Ultane® and outside of the United States primarily under the trademark
Sevorane® and in a few other markets as Ultane®), isoflurane, and enflurane;
· the specialty injectables Zemplar®, for the treatment of hyperparathyroidism,
Calcijex®, and Survanta®;
· Lupron®, also marketed as Lucrin®, and Lupron Depot® used for the palliative
treatment of advanced prostate cancer, treatment of endometriosis and central
precocious puberty, and for the preoperative treatment of patients with anemia
caused by uterine fibroids;
· Ogastro®, also marketed as Prevacid® (lansoprazole), a proton pump inhibitor
for the short-term treatment of duodenal ulcers, gastric ulcers, and erosive
esophagitis; and
· various cardiovascular products, including Mavik® (also marketed as Goptin®),
Isoptin® and Tarka® for the treatment of hypertension.